Business Wire

AGIC-CAPITAL

30.11.2022 08:01:41 CET | Business Wire | Press release

Share
AGIC Capital Acquires Majority Stake in ATEC Pharmatechnik GmbH

AGIC Capital ("AGIC"), a growth-oriented private equity firm with $2.2 billion of assets under management, today announced that it had acquired a majority stake in ATEC Pharmatechnik GmbH ("ATEC" or "the Company"). The sellers, ATEC’s founder & CEO, Hans-Werner Mumm, and family-backed Mittelstand investor HANNOVER Finanz Group, will remain invested in the Company, and Hans-Werner Mumm will continue to act as its CEO.

ATEC is a leading manufacturer of aseptic processing solutions, primarily used in pharmaceutical manufacturing and bioprocessing applications, with a customer base that includes the top 10 global pharmaceutical companies. ATEC's products include stopper and cap processing systems used for aseptic filling, RTP transfer ports and ancillary single-use transfer bag solutions. These mission-critical technologies enable ATEC's customers to establish safe and reliable manufacturing process environments.

This is anticipated to be the first of several acquisitions as AGIC builds a specialty process technologies platform focused on pharmaceutical and biopharmaceutical end markets.

Hans-Werner Mumm, CEO of ATEC commented, "We are excited to partner with AGIC, a firm that shares our passion for providing our customers with safer aseptic transfer technologies, which are critical to the future of medicine. We look forward to expanding our critical role in pharmaceutical manufacturing and bioprocessing as we invest in our next phase of growth."

Erik Yankulin, Managing Director at AGIC, added, "ATEC supports the production of life-saving therapies by providing best-in-class aseptic transfer technologies to pharmaceutical and biopharmaceutical companies. Specifically, the Company's products provide industry-leading solutions for handling sterile drug products across the most demanding pharmaceutical manufacturing applications in the areas of diabetes, oncology and other therapies. We are excited to support ATEC through investments into new product development, go-to-market capabilities, and add-on acquisitions."

Frank Löffler, Partner at HANNOVER Finanz added, “We have worked closely with Hans-Werner and ATEC’s management team since 2018 to grow the business, its customer base and innovative product offering. We strongly believe in the company’s potential and wish AGIC as the future majority shareholder the best of success in driving the next chapter of ATEC’s growth.”

ATEC and HANNOVER Finanz were advised by Macquarie Capital with Latham & Watkins LLP advising the sellers, while AGIC was supported by White & Case LLP in connection with the acquisition.

About AGIC Capital
AGIC is a growth-oriented private equity firm that seeks to invest in thriving middle-market businesses focused on advanced industrial and healthcare technologies in Europe & beyond. AGIC’s differentiated investment strategy combines deep business model expertise, proactive thematic research, an unrelenting focus on the upside and a collaborative, management-first approach to value creation. Launched in 2015, AGIC currently has $2.2 billion in assets under management. The firm's more than 25 professionals are based in Europe and Asia. For more information about AGIC's investment philosophy, visit www.agic-group.com.

About ATEC Pharmatechnik GmbH
ATEC Pharmatechnik GmbH is a leader in stopper and cap processing solutions used for aseptic filling with patented process technology in pharmaceutical applications. ATEC’s products are used primarily in pharmaceutical manufacturing and bioprocessing applications and comprise stopper and cap processing systems used for aseptic filling, RTP transfer ports and ancillary single-use transfer bags and spare parts. The Company is headquartered in Sörup, Germany. www.atecgroup.de

About HANNOVER Finanz
HANNOVER Finanz Group has been a sought-after private equity partner for medium sized enterprises in all industries for more than 40 years now. The private equity firm is based in Hanover and Vienna and was founded in 1979 as one of the first providers of venture capital in Germany. Currently, the HANNOVER Finanz Group has over 700 million Euros of assets under management across around 40 companies in Germany and Austria. Since its foundation, the Group has invested an accumulated total of over one and a half billion Euros and has successfully completed more than 250 projects. For more information, please visit www.hannoverfinanz.de

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005602/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release

Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en

Banma Intelligence and Alipay Launch AI Cockpit Solution Powered by Alipay AI Pay, Enabling Seamless and Secure In-Car Transactions by Voice24.4.2026 16:04:00 CEST | Press release

At the 2026 Beijing International Automotive Exhibition (“Auto China 2026”), OS and AI technology company Banma Intelligence and Alipay today launched a new AI cockpit solution integrating Alipay AI Pay, enabling drivers to complete purchases by voice command directly from their vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424618328/en/ Industry-first AI Cockpit Solution with Alipay AI Pay Unveiled “In the past two years, smart cockpits have achieved rapid advances in perception and decision-making,” said Ming Cai, Banma Intelligence Chief Product Officer. “With large models onboard, vehicles can understand user intent and make recommendations. By integrating Alipay AI Pay into our AI cockpit solution, we are removing the last friction point in the in-car smart cockpit experience - drivers simply speak to pay, no phone required.” The new AI cockpit solution initially covers two high-frequency use cases: enterta

Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 15:21:00 CEST | Press release

Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye